Analyst Ratings

Upgrades, downgrades, and outlook changes from major analysts.

Coverage of analyst actions including upgrades, downgrades, initiations, and price-target changes. This category tracks how institutional research influences market perception, momentum shifts, and short-term price behavior.

Articles

3,518 total articles

Piper Sandler Sticks With Overweight on LivaNova, Cites FY26 Upside

Piper Sandler Sticks With Overweight on LivaNova, Cites FY26 Upside

Piper Sandler reaffirmed an Overweight rating and an $85 price target on LivaNova (LIVN), pointing to upside in fiscal 2026 driven by reimbursement improvements for VNS therapy and momentum in cardiopulmonary sales. The firm expects a fourth-quarter beat, projects mid-single-digit revenue growth ex-FX for FY26 and sees room for multiple expansion i…